Oxford Biomedica Share News (OXB)

BRIEF-Oxford BioMedica studies Trovax in mesothelioma

LONDON, June 24 (Reuters) - Oxford BioMedica PLC: * Announces collaborative phase I/II study to evaluate Trovax in mesothelioma, with a tea
[24 Jun '10]

BRIEF-Oxford Biomedica agrees timing of royalties to CRT

LONDON, June 18 (Reuters) - Oxford Biomedica PLC: * Announces amendment to 5t4 licence agreement with cancer research technology * Roy
[18 Jun '10]

BRIEF-Oxford Bio drug shows good 2-yr results in Parkinson's

LONDON, June 14 (Reuters) - Oxford Biomedica PLC: * Two-year phase I/II results of ProSavin in Parkinson's shows sustained improveme
[14 Jun '10]

BRIEF-Oxford Biomedica says net cash of 21.3 mln stg

LONDON, May 19 (Reuters) - Oxford Biomedica PLC: * At 31 March 2010 the company had a net cash1 balance of £21.3 million * Partnership
[19 May '10]

BRIEF-Oxford BioMedica ends 2009 with more cash

LONDON, March 10 (Reuters) - Oxford BioMedica PLC: * Year net loss before exceptional items of £9.5 million (2008: £5.5 million) * Net
[10 Mar '10]

BRIEF-Oxford Biomedica extends gene therapy collaboration

LONDON, Jan 27 (Reuters) - Oxford Biomedica PLC: * Oxford Biomedica Plc and ALS Therapy Development Institute extend collaboration to devel
[27 Jan '10]

UPDATE 1-Oxford Bio says ProSavin promising; shares double

LONDON, Oct 15 (Reuters) - British gene therapy specialist Oxford BioMedica said on Thursday patients had responded well to the second dose of i
[15 Oct '09]

STOCKS NEWS UK-Oxford BioMedica soars on Parkinson's data

STOCKS NEWS Reuters Results diary Europe Real-time Equity News
[15 Oct '09]